Kiora grants Senju exclusive option for KIO-301 in Asia; $1.25M upfront, up to $110M milestones plus royalties

KIORA PHARMACEUTICALS INC

Immediate $1.25M option payment; if exercised, mid-single-digit million upfront and up to $110M in development, regulatory, and commercial milestones.
Tiered royalties from high single-digit to high teen percent on net sales; territory covers Japan, China, and other key Asian countries.
Option exercisable after topline data from ongoing ABACUS-2 Phase 2 trial; Senju to collaborate with Théa, Kiora's ex-Asia partner.
Combined deal value with Théa (2024) and Senju exceeds $400M plus royalties; cash runway extended into late 2027.
KIO-301 is a molecular photoswitch for retinitis pigmentosa and other inherited retinal diseases, currently in Phase 2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.